Houston digital health platform raises additional seed funding from fresh investors

money moves

Koda Health has raised funding to fuel growth of its digital advance care planning company. Image via kodahealthcare.com

A Houston-born digital advance care planning company, has secured new funding from some big names.

Koda Health achieved a successful oversubscription of additional seed round funding thanks to the participation of AARP, Memorial Hermann Health System, and the Texas Medical Center Venture Fund. The total amount raised was undisclosed, and the round was led by Austin-based Ecliptic Capital.

The tech platform improves planning for serious illness treatment and end-of-life care using a cloud-based advance care planning, or ACP, platform that pairs with in-house support. Essentially, it allows patients to do their planning ahead and make sure that their wishes are actually put into action. According to Koda Health, this results in an average of $9,500 saved per-patient, as well as improved health outcomes.

"If we’re looking at speed of market adoption, it’s clear that Koda Health is at the forefront of a crucial transformation in Advance Care Planning," says Tatiana Fofanova, PhD, CEO of Koda Health, in a press release. “In just a few years, we’ve built out a product that now serves well over 700,000 patients nationwide for industry giants like Cigna, Privia and Houston Methodist.”

Dr. Desh Mohan, the chief medical officer for Koda Health says that it was important to the company to create strategic partnerships with its investors. In fact, Memorial Hermann isn’t just helping with funding. The hospital system is also collaborating with Koda on a new pilot project.

“Koda is uniquely positioned to serve payers, providers and patients,” adds William McKeon, president and CEO of Texas Medical Center. “We rarely see a company that provides value to all three stakeholders. Seeing Koda launch from our TMCi BioDesign program to the progress they've made with our member institutions and players in the value chain is incredible.”

Beyond the TMC, Koda’s collaboration with AARP goes through the latter’s AgeTech Collaborative. That ecosystem unites founders in the realm of longevity tech to make meaningful change in their field.

"AARP research shows that there is a willingness among older adults in the U.S. to prepare for the end of their lives," says Amelia Hay, VP of Startup Programming and Investments at AgeTech Collaborative. "This indicates a need for more programs and services geared towards ensuring adults take the necessary steps, and AARP is pleased to invest in Koda Health to help address that need."

Koda raised its first seed funding in 2022, a round that totaled $3.5 million. The new round close means that Koda can accelerate its efforts to modernize ACP.

Softeq has named three members to its executive team. Photos courtesy of Softeq

Houston tech company adds 3 members to its C-suite

growing team

A tech development company has expanded its executive suite with three new additions to its team.

Softeq Development Corp. has hired Craig Ceccanti as COO, Albert Esser as chief delivery officer, and Edwin Lemus as chief people officer. The new hires' roles were effective as of June 1. The Houston company, founded in 1997, creates hardware and software solutions for its clients. Softeq also runs a venture fund and studio for startups from around the world.

“With the significant growth of our engineering services business plus the addition of our Venture Studio and $40 million Venture Fund, we saw an opportunity to welcome new leaders with global experience and fresh thinking to continue evolving our business and scaling for the future,” says Christopher A. Howard, founder and CEO of Softeq, in a news release. “This is a huge investment in our team, and with the addition of these three leaders to our C-suite we will centralize our global leadership team in Houston while providing support and expertise to our team across 22 countries and clients worldwide.”

About the new executives:

  • Craig Ceccanti is a serial entrepreneur. He founded Pinot’s Palette and oversaw its franchise growth and exit before joining the founding team of sEATz — now Rivalry Technologies. The sports tech startup provides a mobile ordering software for stadiums, as well as hospital and hospitality destinations. Most recently, he founded and ran T-Minus Solutions, a custom software development company. As COO, Ceccanti will oversee the day-to-day operations of Softeq and work to improve internal and external processes.
  • With three decades of experience in tech and consulting at Daimler AG, GE, Emerson, Hilti, and Dell, Albert Esser will lead the delivery organization, which includes including solutions engineering, project management, and resource management. As chief delivery officer, he's tasked with expanding "the team’s capabilities and agility by adding to the global network of consultants," per the release, as well as leading Softeq's adoption of emerging new technologies like IoT, AI/ML, vision systems, industrial automation, robotics, cloud applications, and cyber security.
  • Edwin Lemus has 22 years of talent-related experience, and, as chief people officer, he will continue to grow the Softeq team and build a company culture for the workforce that stretches across 22 offices around the world.

Softeq Venture Studio launched over a year ago with its inaugural cohort in 2021, and the fund was launched last year. The latest cohort was announced in March.

Nine companies committed to Houston Exponential's first round of funding. Shobeir Ansar/Getty Images

Houston Exponential's ambitious venture fund closes first round with $25 million

Money moves

Houston Exponential closed the first round of funding for its fund of funds with $25 million in commitments from nine companies. The money will go to non-Houston venture capitalists to invest back into Houston startups.

HX Venture Fund's first-round partners include: Insperity, Chevron, Shell, Quanta Services, Westlake Chemical, The Plank Companies, PROS, HEB, and Camden.

Kingwood-based Insperity was the anchor investor, committing to $5 million last October, according to the release. The company also provided an undisclosed amount of resources support the operations of the fund as it launched.

"This is another transformational moment for Houston," says Gina Luna, chair of Houston Exponential, in the release. "From day one at Houston Exponential, we have been executing a plan to accelerate the growth of the ecosystem, including connecting Houston startups with the capital they need to grow their businesses. This is a significant, tangible milestone. Houston's leading companies have stepped up in a big way to make this happen, and this is a clear signal that Houston is committed to success."

Houston-based venture capital firm Mercury Fund's co-founder and managing director, Blair Garrou, chaired the fund's advisory board. He's also a board member for HX.

The fund of funds won't donate to Houston organizations directly, Garrou says in a statement. The fund's organizers had a different approach to growing funds in Houston's startup space.

"The HX Venture Fund will invest in venture capital funds outside of Houston – generating investment and interest in the region while increasing the investable capital available to Houston-based startups," says Garrou. "The HX Venture Fund is built upon a proven model that provides multiple benefits to its investors."

The benefitting venture capital funds haven't yet been named.

HX modeled the fund after the Renaissance Venture Capital Fund in Michigan, from which 10 outside venture capital firms benefitted —Mercury Fund was one of the 10. It was Garrou who led the movement to get Renaissance Fund's CEO and Fund Manager, Chris Rizik, as a part of the HX Venture Fund from the start as a member of the investment committee.

The Michigan fund launched 9 years ago and exceeded all expectations. For ever dollar Rizik and his team invested, $17 came back into the Michigan area, he told the Houston Business Journal. He says Houston has the same potential.

"I've spoken to many cities about Renaissance's fund of funds model and the impact it has had on Michigan," says Rizik in the release. "Houston has leaned into this model and it is impressive what they have been able to accomplish in a short time. It is a testament to the commitment of Houston's business and tech leaders to growing the ecosystem. It's really exciting to see."

In October 2017, Houston Exponential was launched by Mayor Sylvester Turner's Innovation and Technology Task Force in collaboration with the Greater Houston Partnership's Innovation Round Table and the Houston Technology Center. HX's launch included three main goals, according to the release: "make Houston a top 10 innovation ecosystem, generate $2 billion in venture capital annually and create 10,000 new technology jobs a year by 2022."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings